Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: Identification of analogues with cellular activity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 5, 2003, Pages 971-975

  Larsen, Scott D ^a   Stevens, F Craig ^a   Lindberg, Thomas J ^a   Bodnar, Paul M ^a   O'Sullivan, Theresa J ^a   Schostarez, Heinrich J ^a   Palazuk, Barbara J ^a   Bleasdale, John E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; PHENYLALANINE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; TERT BUTYLOXYCARBONYLPHENYLALANINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL LINE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; GLUCOSE TRANSPORT; MOLECULAR WEIGHT; MUSCLE CELL; NONHUMAN; RAT;

EID: 0037430643     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01065-X     Document Type: Article

References (16)

1. Kruszynska Y.T., Olefsky J.M. J. Invest. Med. 44:1996;413.
2. Ukkola O., Santaniemi M. J. Int. Med. 251:2002;467.
3. Salmeen A., Andersen J.A., Myers M.P., Tonks N.K., Barford D. Molec. Cell. 6:2000;1401.
4. (a) Blaskovich M.A., Kim H.-O. Expert Opin. Ther. Pat. 12:2002;871
5. (b) Johnson T.O., Ermolieff J., Jirousek M.R. Nat. Rev. - Drug Discov. 1:2002;696.
6. Bleasdale J.E., Ogg D., Palazuk B.J., Jacob C.S., Swanson M.L., Wang W.-Y., Thompson D.P., Conradi R.A., Mathews W.R., Laborde A.L., Stuchly C.W., Heijbel A., Bergdahl K., Bannow C.A., Smith C.W., Liljebris C., Schostarez H.J., May P.D., Stevens F.C., Larsen S.D. Biochemistry. 40:2001;5642.
7. Larsen S.D., Barf T., Liljebris C., May P.D., Ogg D., O'Sullivan T.J., Palazuk B.J., Schostarez H.J., Stevens F.C., Bleasdale J.E. J. Med. Chem. 45:2002;598.
8. Larsen, S. D.; May, P. D.; Bleasdale, J. E.; Liljebris, C. L.; Schostarez, H. J.; Barf, T. Preparation of substituted phenylalanine derivatives as protein tyrosine phosphatase inhibitors. WO 9911606, 11 March 1999.
9. Liljebris C., Larsen S.D., Ogg D., Palazuk B.J., Bleasdale J.E. J. Med. Chem. 45:2002;1785.
10. 37: prepared from MOM-protected L-Boc-serine, which was made by saponification of the corresponding methyl ester (Hanessian, S.; Ninkovic, S. J. Org. Chem. 1996, 61, 5418).
11. 39: prepared from MOM-protected L-Boc-homoserine, which was made from L-Boc-homoserine methyl ester (Howarth, N. M.; Wakelin, L. P. G. J. Org. Chem. 1997, 62, 5441) by protection with MOMCl (DIEA, DCM) followed by saponification.
12. 40: prepared from TBDMS-protected L-Boc-homoserine (Altmann, K.-H.; Chiese, C. S.; Garcia-Echeverria, C. Bioorg. Med. Chem. Lett. 1997, 7, 1119).
13. Drysdale M.J., Pritchard M.C., Horwell D.C. J. Med. Chem. 35:1992;2573.
14. 2H.
15. 5 Data were normalized to cell lysate protein recovered and are expressed as (net insulin-dependent glucose transport in the presence of PTP1B inhibitor-net insulin-dependent glucose transport in the absence of PTP1B inhibitor)×100%. A value of 120% or higher was considered a significant increase.
16. Kole H.K., Liotta A.S., Kole S., Roth J., Montrose-Rafizadeh C., Bernier M. J. Biol. Chem. 271:1996;31619.